 phase new cisplatin deriv hematolog malign dwa new deriv platin compound phase II studi solid tumor japan dose-limit factor myelotox mild extramedullari toxic phase adult patient relaps hematolog malign patient total treatment cours dwa dose hour continu infus dose clinic toxic urinari excret studi dwa success day type administr day diarrhea nausea vomit parenter fluid nutrit support dose-limit factor schedul gastrointestin toxic myelotox toler patient acut nonlymphocyt leukemia anll complet remiss patient chronic myelogen leukemia cml crisi chronic phase phase II trial dwa hematolog malign myeloid diseas